Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LenPem Cervix: Pembrolizumab and Lenvatinib in Metastatic and Recurrent Cervix Cancer
NCT06266338Phase 2Recruiting
- Sponsor
- UT Southwestern Medical Center
- Start
- Mar 2024
- Primary completion
- Oct 2026
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pembrolizumab and lenvatinib in Cervical Cancer (CC), sponsored by UT Southwestern Medical Center. Primary endpoint: Objective Response Rate at 36 months. Started Mar 2024; status: recruiting.
02
Drugs
pembrolizumablenvatinib
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on NCT06266338.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06266338.